PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection-Reference-Cited by-同舟云学术

PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection

Published:2018-04-20 Issue:3 Volume:19 Page:85-93
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Dhody Kush¹^ORCID,Pourhassan Nader²^ORCID,Kazempour Kazem¹^ORCID,Green Derry¹^ORCID,Badri Shide¹,Mekonnen Hana¹,Burger Denis²^ORCID,Maddon Paul J.³^ORCID

Affiliation:

1. Amarex Clinical Research LLC, Germantown, MD, USA

2. CytoDyn Inc., Vancouver, WA, USA

3. Maddon Advisors LLC, Scarsdale, NY, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

https://www.tandfonline.com/doi/pdf/10.1080/15284336.2018.1452842

Reference19 articles.

1. Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140

2. Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5

3. Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors

4. Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)

5. Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fc‐FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement;Immunological Reviews;2024-09-13

2. Antiviral Protein–Protein Interaction Inhibitors;Journal of Medicinal Chemistry;2024-02-23

3. Broadly neutralizing antibodies targeting HIV: Progress and challenges;Clinical Immunology;2023-12

4. Monoclonal CCR5 Antibody: A Promising Therapy for HIV;Current HIV Research;2023-03

5. Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19;PLOS Pathogens;2022-06-24